We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Matthew
Frise
+44 (0)118 322 8840
matthew.frise@royalberkshire.nhs.uk
Dr
Craig
Hughes
+44 (0)118 378 8169
c.e.hughes@reading.ac.uk
Miss
Tyler
Horn
+44 (0)118 378 8169
tyler.horn@royalberkshire.nhs.uk
Liver disease, critical illness, platelet function
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
The blood that circulates within our bodies consists of many different cells, each with unique functions. One type of blood cell is the platelet; these cells become activated and attach to sites of injury to help form a blood clot and reduce or prevent further bleeding. In some unwell individuals, the number and/or function of these platelets can become altered. In many critically ill patients, the number of platelets can be reduced below a safe level, a condition known as thrombocytopenia. Thrombocytopenia is problematic, as in many cases, it is linked to worse patient outcomes. Within critically unwell patients, one group at risk of both thrombocytopenia and other bleeding disorders (e.g. overactivation of clotting) are patients with liver disease. Patients with liver disease in the Intensive Care Unit (ICU) at the Royal Berkshire Hospital (RBH) include those with established diseases such as alcohol-related cirrhosis, as well as those with liver dysfunction as part of their critical illness, for example, patients with sepsis. In this study, RBH and the University of Reading will collaborate to analyse the platelets using a range of complex, state-of-the-art techniques to study blood samples taken from patients with liver disease and critically unwell patients in the ICU at RBH. The goal is to analyse their platelet function in the laboratory and monitor how the function changes throughout their time in the ICU. This information will allow us to relate patient experiences, such as bleeding, clotting, and organ dysfunction, back to the laboratory results. While participation in this study will not have immediate benefits for the patients, upon the completion of this study, its results will be used to support future studies in making improvements to treatment strategies for this patient category.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
1. Patients on P2Y12 inhibitors (including clopidogrel, ticagrelor and prasugrel) 2. Patients on treatment-dose anticoagulation, including warfarin or novel anticoagulant drugs 3. Patients under 18 years of age 4. Active or recent malignancy (< 1 year) or on active treatment
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
This information has not yet been provided by the study team. You'll have an opportunity to discuss any risks and benefits that may be associated with this study prior to consenting to taking part.
Dr
Craig
Hughes
+44 (0)118 378 8169
c.e.hughes@reading.ac.uk
Miss
Tyler
Horn
+44 (0)118 378 8169
tyler.horn@royalberkshire.nhs.uk
Dr
Matthew
Frise
+44 (0)118 322 8840
matthew.frise@royalberkshire.nhs.uk
The study is sponsored by Royal Berkshire NHS Foundation Trust and funded by University of Reading Healthcare Innovation Partnership.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
